Related Experiment Video
Updated: Sep 25, 2025
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.4K
Significant decrease in plasmad-dimer levels and mean platelet volume after a 3-month treatment with rosuvastatin in
Toktam Alirezaei1, Haniyeh Sattari2, Rana Irilouzadian2
1Clinical Research Development Unit of Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clinical Cardiology
|April 28, 2022
Summary
Rosuvastatin treatment significantly reduced D-dimer and mean platelet volume (MPV) in venous thromboembolism (VTE) patients. This suggests statins may help reduce systemic inflammation and recurrent VTE.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Inflammation is implicated in venous thromboembolism (VTE) initiation and recurrence.
- Statins possess anti-inflammatory properties, but their impact on D-dimer in VTE is debated.
Purpose of the Study:
- To assess rosuvastatin's effect on D-dimer and inflammatory markers in VTE patients.
- To investigate rosuvastatin's potential role in managing VTE-associated inflammation.
Main Methods:
- A prospective, randomized study involved 228 VTE patients.
- The intervention group received rosuvastatin 10mg daily for 3 months alongside conventional treatment.
- Serum markers were measured at baseline and after 3 months.
Main Results:
- Rosuvastatin significantly decreased plasma D-dimer levels.
- Mean platelet volume (MPV) also showed a significant reduction in the rosuvastatin group.
- No significant changes were observed in neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio.
Conclusions:
- Daily rosuvastatin (10mg) for 3 months effectively lowers D-dimer and MPV in VTE patients.
- These findings support statins' potential to mitigate systemic inflammation in VTE.
- This may contribute to reducing the recurrence rate of VTE.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
34
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
34
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
920
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
920
01:26Atherosclerosis III: Management
51
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
51
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
49
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
49
01:30Venous Thrombosis I: Introduction
49
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
49
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
660
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
660